Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
pubmed:
10
3
2022
medline:
16
7
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
Widespread use of the measles vaccine should lead to the elimination of this disease. Here, we study the seroprevalence of measles in a cohort of adults living with HIV born after the introduction of measles vaccine in France and attempt to identify risk factors for the absence of serum measles antibody. In this multi-centre cross-sectional study, adult outpatients born after 1980 were screened for the presence of measles IgG antibody. Demographic and clinical data were obtained from the standardized electronic medical record system. Univariate and multivariate logistic regressions were performed to identify factors associated with the absence of measles antibodies. Between April 2019 and April 2020, 648 participants were enrolled. The median age was 33 years, 53.6% were born outside of France, and 74% were considered as socially deprived. Plasma HIV RNA was undetectable in 86% of patients. Among 603 evaluable patients, measles serology was positive in 87.2%. Only 81.8% of the patients with documented vaccination tested positive for measles IgG. Younger age was significantly associated with the absence of measles serum antibodies ( P = 0.004 for each 10-year lower), as was birth in France ( P < 0.001) and absence of social vulnerability ( P = 0.04). The current study revealed a low seroprevalence of measles compared with that previously reported in France 6 years earlier and to the expected rate to achieve herd immunity. Checking vaccination record should be systematically carried out in patients living with HIV to fill the immunity gaps.
Identifiants
pubmed: 35262533
doi: 10.1097/QAD.0000000000003220
pii: 00002030-202207150-00008
doi:
Substances chimiques
Antibodies, Viral
0
Measles Vaccine
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1273-1278Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012–2020 midterm review . Vaccine 2018; 36: (Suppl 1): A1–A34.
World Health Organization (WHO). Global measles and rubella strategic plan: 2012–2020 . 2012; Geneva, Switzerland: WHO, Available at: https://www.who.int/publications/i/item/9789241503396 [Accessed on 10 June 2021].
World Health Organization. Measles vaccines: WHO position paper, April 2017 – recommendations . Vaccine 2019; 37:219–222.
[No authors listed]. Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 – conclusions and recommendations . Wkly Epidemiol Rec 2014; 89:1–20.
World Health Organization. Measles-Ukraine. Measles-European Region. Disease outbreak news; updated 6 May 2019. https://www.who.int/emergencies/disease-outbreak-news/item/2019-DON140 . [Accessed 9 March 2022]
Santé publique France. Données de couverture vaccinale rougeaole rubéole oreillons par groupe d’âge; updated 2020 Nov 24. https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-couverture-vaccinale-rougeole-rubeole-oreillons-par-groupe-d-age . [Accessed 10 June 2021]
Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients . JAMA 1992; 267:1237–1241.
Markowitz LE, Chandler FW, Roldan EO, Saldana MJ, Roach KC, Hutchins SS, et al. Fatal measles pneumonia without rash in a child with AIDS . J Infect Dis 1988; 158:480–483.
Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature . Clin Infect Dis 1993; 16:654–660.
Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM, Villasís-Keever A, Cuellar-Rodríguez J, Mosqueda-Gómez JL, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART . Vaccine 2009; 27:7059–7064.
Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand . BMC Infect Dis 2016; 16:190.
Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-infected adults . Vaccine 1994; 12:1222–1224.
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP) . MMWR Recomm Rep 2013; 62 (RR-04):1–34. Erratum in: MMWR Recomm Rep 2015; 64(9): 259.
2015 British HIV Association. British HIV Association guidelines on the use of vaccines in HIV-positive adults; 2015. https://www.bhiva.org/file/NriBJHDVKGwzZ/2015-Vaccination-Guidelines.pdf . [Accessed 9 June 2021]
European AIDS Clinical Society. EACS Guidelines. EACS Guidelines, version 11.0; October 2021. https://www.eacsociety.org/guidelines/eacs-guidelines . [Accessed 22 October 2021]
Sass C, Dupré C, Dauphinot V, Labbe E, Guégen R, Gerbaud L, et al. Le score EPICES: un score individual de précarité. Construction du score et mesure des relations avec des données de santé dans une population de 197 389 personnes . Bull Epidémiologique Hebd 2006; 14:93–96.
Raho-Moussa M, Guiguet M, Michaud C, Honoré P, Palacios C, Boué F, et al. Respective roles of migration and social deprivation for virological nonsuppression in HIV-infected adults on antiretroviral therapy in France . PLoS One 2019; 14:e0213019.
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort . HIV Med 2009; 10:504–511.
Antona D, Morel P, Jacquot C, Fonteneau L, Dina J, Vauloup-Fellous C, et al. Measles and rubella seroprevalence in a population of young adult blood donors, France . Epidemiol Infect 2019; 147:e109.
Parent du Chatelet I, Levy Bruhl D. Surveillance de la rougeole en France. Bilan etevolution en vue de l’elimination de la maladie, Santé publique France. 2004; updated 6 September 2019. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-prevention-vaccinale/rougeole/documents/rapport-synthese/surveillance-de-larougeole-en-france.-bilan-et-evolution-en-vue-de-l-elimination-de-la-maladie . [Accessed 9 June 2021]
Loevinsohn G, Rosman L, Moss WJ. Measles seroprevalence and vaccine responses in Human Immunodeficiency Virus-infected adolescents and adults: a systematic review . Clin Infect Dis 2019; 69:836–844.
Rearigh L, O’Neill J, Kubat M, Sayles H, Swindells S, Bares SH. Surprisingly low levels of measles immunity in persons with HIV: a seroprevalence survey in a United States HIV clinic . Open Forum Infect Dis 2020; 7:ofaa428.
Kemper CA, Gangar M, Arias G, Kane C, Deresinski SC. The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California . J Infect Dis 1998; 178:1177–1180.
Kennedy RB, Ovsyannikova IG, Thomas A, Larrabee BR, Rubin S, Poland GA. Differential durability of immune responses to measles and mumps following MMR vaccination . Vaccine 2019; 37:1775–1784.
Patel MK, Orenstein WA. Classification of global measles cases in 2013–17 as due to policy or vaccination failure: a retrospective review of global surveillance data . Lancet Glob Health 2019; 7:e313–e320.
Bolotin S, Hughes SL, Gul N, Khan S, Rota PA, Severini A, et al. What is the evidence to support a correlate of protection for measles? A systematic review . J Infect Dis 2020; 221:1576–1583.
Linnemann CC Jr. Measles vaccine: immunity, reinfection and revaccination . Am J Epidemiol 1973; 97:365–371.
Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity . Pediatr Infect Dis J 1990; 9:101–110.
Cherry JD, Feigin RD, Lobes LA Jr, Shackelford PG. Atypical measles in children previously immunized with attenuated measles virus vaccines . Pediatrics 1972; 50:712–717.